Catalyst Health Ventures

Lena Health is a developer of a text-based virtual assistant platform designed to assist patients, particularly those with chronic conditions. The platform leverages conversational AI to facilitate care coordination and navigation tasks, while also providing the option for human support when needed. By allowing patients to schedule appointments and manage their health via SMS text live chat, Lena Health offers a convenient alternative to lengthy phone calls. This service is especially beneficial for value-based care organizations and payers, as it enhances medication adherence and aims to improve overall health outcomes for its members.

Esperto Medical is a medical device company based in Irvine, California, focused on developing advanced wearable diagnostic tools for both hospital and remote patient monitoring. The company utilizes a proprietary technology called resonance sonomanometry, which employs acoustic stimulation to measure blood pressure continuously and noninvasively, eliminating the need for calibration. By offering round-the-clock monitoring capabilities, Esperto Medical aims to enhance patient care and accessibility, allowing individuals to track their vital signs conveniently from home or within clinical settings.

Venova Medical specializes in developing vascular access systems aimed at improving the experience of patients requiring renal replacement therapy, particularly those needing hemodialysis. Founded in 2018 and based in Los Gatos, California, the company focuses on overcoming challenges related to vascular access creation. By addressing both patient-level and systemic barriers, Venova Medical provides solutions that facilitate quicker functioning access with reduced need for intervention. This approach not only enhances vascular access outcomes but also aims to lower associated costs, ultimately simplifying the process for patients in need of hemodialysis.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Avive Solutions is a company that develops an advanced Automated External Defibrillator (AED) aimed at improving survival rates from sudden cardiac arrest (SCA). Their device is designed to be portable, affordable, and user-friendly, ensuring that anyone can effectively respond to an SCA incident. In addition to the AED, Avive offers a connected software platform that facilitates the transfer of critical incident data to emergency services and healthcare professionals, enhancing the overall response to cardiac emergencies. By addressing the challenges associated with SCA, Avive Solutions aims to empower individuals and organizations to save lives more effectively. The company is based in Brisbane, California.

Instylla is a Bedford, Massachusetts-based medical equipment supplier specializing in next-generation liquid embolics for interventional radiology. The company focuses on developing innovative embolization products that enhance patient outcomes, particularly in applications such as peripheral hemostasis and interventional oncology. Its flagship product, the Embrace Hydrogel Embolic System, is designed to facilitate controlled, complete, and persistent embolization, providing healthcare professionals with advanced tools for effective treatment in various clinical scenarios.

Rejoni, Inc. is a medical device company specializing in gynecological surgical procedures, focusing on the development and commercialization of products that reduce the risk of scar formation after intrauterine interventions. Founded in 2020 and based in Bedford, Massachusetts, Rejoni aims to enhance the outcomes of both minimally invasive and traditional gynecological surgeries. By utilizing biomaterials, the company seeks to address both acute and chronic risks associated with these procedures, ultimately providing women with technologies that support their overall health and well-being.

Avive Solutions is a company that develops an advanced Automated External Defibrillator (AED) aimed at improving survival rates from sudden cardiac arrest (SCA). Their device is designed to be portable, affordable, and user-friendly, ensuring that anyone can effectively respond to an SCA incident. In addition to the AED, Avive offers a connected software platform that facilitates the transfer of critical incident data to emergency services and healthcare professionals, enhancing the overall response to cardiac emergencies. By addressing the challenges associated with SCA, Avive Solutions aims to empower individuals and organizations to save lives more effectively. The company is based in Brisbane, California.

Epitel is a digital health company focused on developing a wearable, wireless EEG monitoring platform aimed at improving seizure detection. The company offers a brain health monitoring device that accurately identifies abnormal brain activities using a proprietary cloud-based wearable sensor system combined with advanced artificial intelligence technologies. This innovative approach provides accessible, affordable, and reliable electrographic seizure detection, allowing physicians, caregivers, and patients with neurological disorders to gain valuable insights into brain health. By enhancing the quality of life and care for individuals affected by these conditions, Epitel strives to make significant contributions to the field of digital health.

PanTher Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative drug-delivery treatments for cancer. The company has created a proprietary platform that enables targeted and sustained drug administration directly at tumor sites, significantly enhancing therapeutic efficacy while minimizing the toxic side effects commonly associated with traditional chemotherapy. This approach allows oncologists to unlock the full potential of cancer drugs, particularly in challenging cases such as pancreatic cancer, where treatment options can be limited. Founded in 2014, PanTher Therapeutics aims to improve cancer care by addressing the needs of patients suffering from life-threatening malignancies.

Instylla is a Bedford, Massachusetts-based medical equipment supplier specializing in next-generation liquid embolics for interventional radiology. The company focuses on developing innovative embolization products that enhance patient outcomes, particularly in applications such as peripheral hemostasis and interventional oncology. Its flagship product, the Embrace Hydrogel Embolic System, is designed to facilitate controlled, complete, and persistent embolization, providing healthcare professionals with advanced tools for effective treatment in various clinical scenarios.

Conformal Medical, Inc. is a medical device company focused on developing innovative solutions to prevent stroke in patients with atrial fibrillation, particularly those with non-valvular atrial fibrillation. Founded in 2016 and based in Nashua, New Hampshire, the company offers CLAAS Technology, which is designed for sealing the left atrial appendage (LAA). This proprietary technology aims to enhance the effectiveness of left atrial appendage closure, addressing a critical need in the management of atrial fibrillation.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, founded in 2010 by Drs. John Scandurra and Karl Vollmers. The company specializes in developing an implantable cardiovascular device aimed at treating pulmonary arterial hypertension (PAH). This innovative device is designed to reduce the workload on the right side of the heart, potentially enhancing both survival rates and the quality of life for patients suffering from this condition. Aria CV holds an exclusive license for certain patents from the University of Minnesota, reflecting its strong ties to academic research and innovation in the field of medical devices.

Conformal Medical, Inc. is a medical device company focused on developing innovative solutions to prevent stroke in patients with atrial fibrillation, particularly those with non-valvular atrial fibrillation. Founded in 2016 and based in Nashua, New Hampshire, the company offers CLAAS Technology, which is designed for sealing the left atrial appendage (LAA). This proprietary technology aims to enhance the effectiveness of left atrial appendage closure, addressing a critical need in the management of atrial fibrillation.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

Saphena Medical, Inc. is a medical device company based in West Bridgewater, Massachusetts, founded in 2013. The company specializes in Endoscopic Vein Harvesting technologies, primarily focusing on the cardiovascular field. It offers an innovative product called Venapax, which is an all-in-one system designed to facilitate dissection and simultaneous branch ligation. This system emphasizes a minimal-touch experience while ensuring high specimen quality. Saphena Medical's device features a soft, elastomeric tip that remains closed during dissection, allowing for a smooth transition and improved access. This advancement positions the company's endoscopic vessel harvesting technology at a new level, providing physicians with comprehensive tools for cardiovascular procedures.

Cruzar Medsystems Inc. is a healthcare company based in Braintree, Massachusetts, that specializes in manufacturing medical devices for accessing peripheral vasculature. Established in 2013, the company has developed a device that features a guidewire and an intravascular catheter, which employs a balloon-actuated distal anchoring system alongside an everting lumen. This innovative design allows physicians to effectively cross obstructive lesions and address vascular occlusions, thereby enhancing treatment options in vascular medicine.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

nVision Medical Corporation is a medical device company focused on addressing female health issues, specifically infertility caused by fallopian tube dysfunction and ovarian cancer detection. Founded in 2009 and based in Saratoga, California, nVision Medical develops innovative devices that allow clinicians to assess the health of previously inaccessible areas of the female reproductive tract. The company aims to fill significant gaps in women's health innovation by creating technologies that enhance diagnosis and treatment options. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation, further leveraging resources to advance its mission in the healthcare sector.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Maxwell Health offers a software-as-a-service platform that simplifies employee benefits and human resources for small to mid-sized employers. Founded in 2012 and headquartered in New York, with an additional office in Cambridge, Massachusetts, the company provides a comprehensive online service that includes information on various insurance products such as medical, dental, vision, and life insurance, as well as tools for benefits administration, payroll, and COBRA management. The platform features an intuitive marketplace that streamlines the process of purchasing benefits for employees and includes a mobile application for easy access. Maxwell Health aims to enhance the experience of insurance, financial, and wellness benefits for American families, leveraging its technology through partnerships with benefits advisors and insurance companies. In June 2018, Maxwell Health became a subsidiary of Sun Life Financial United States.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, founded in 2010 by Drs. John Scandurra and Karl Vollmers. The company specializes in developing an implantable cardiovascular device aimed at treating pulmonary arterial hypertension (PAH). This innovative device is designed to reduce the workload on the right side of the heart, potentially enhancing both survival rates and the quality of life for patients suffering from this condition. Aria CV holds an exclusive license for certain patents from the University of Minnesota, reflecting its strong ties to academic research and innovation in the field of medical devices.

Saphena Medical, Inc. is a medical device company based in West Bridgewater, Massachusetts, founded in 2013. The company specializes in Endoscopic Vein Harvesting technologies, primarily focusing on the cardiovascular field. It offers an innovative product called Venapax, which is an all-in-one system designed to facilitate dissection and simultaneous branch ligation. This system emphasizes a minimal-touch experience while ensuring high specimen quality. Saphena Medical's device features a soft, elastomeric tip that remains closed during dissection, allowing for a smooth transition and improved access. This advancement positions the company's endoscopic vessel harvesting technology at a new level, providing physicians with comprehensive tools for cardiovascular procedures.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

Maxwell Health offers a software-as-a-service platform that simplifies employee benefits and human resources for small to mid-sized employers. Founded in 2012 and headquartered in New York, with an additional office in Cambridge, Massachusetts, the company provides a comprehensive online service that includes information on various insurance products such as medical, dental, vision, and life insurance, as well as tools for benefits administration, payroll, and COBRA management. The platform features an intuitive marketplace that streamlines the process of purchasing benefits for employees and includes a mobile application for easy access. Maxwell Health aims to enhance the experience of insurance, financial, and wellness benefits for American families, leveraging its technology through partnerships with benefits advisors and insurance companies. In June 2018, Maxwell Health became a subsidiary of Sun Life Financial United States.

SevenOaks Biosystems, LLC focuses on developing autologous tissue generation equipment.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Maxwell Health offers a software-as-a-service platform that simplifies employee benefits and human resources for small to mid-sized employers. Founded in 2012 and headquartered in New York, with an additional office in Cambridge, Massachusetts, the company provides a comprehensive online service that includes information on various insurance products such as medical, dental, vision, and life insurance, as well as tools for benefits administration, payroll, and COBRA management. The platform features an intuitive marketplace that streamlines the process of purchasing benefits for employees and includes a mobile application for easy access. Maxwell Health aims to enhance the experience of insurance, financial, and wellness benefits for American families, leveraging its technology through partnerships with benefits advisors and insurance companies. In June 2018, Maxwell Health became a subsidiary of Sun Life Financial United States.

Cruzar Medsystems Inc. is a healthcare company based in Braintree, Massachusetts, that specializes in manufacturing medical devices for accessing peripheral vasculature. Established in 2013, the company has developed a device that features a guidewire and an intravascular catheter, which employs a balloon-actuated distal anchoring system alongside an everting lumen. This innovative design allows physicians to effectively cross obstructive lesions and address vascular occlusions, thereby enhancing treatment options in vascular medicine.

nVision Medical Corporation is a medical device company focused on addressing female health issues, specifically infertility caused by fallopian tube dysfunction and ovarian cancer detection. Founded in 2009 and based in Saratoga, California, nVision Medical develops innovative devices that allow clinicians to assess the health of previously inaccessible areas of the female reproductive tract. The company aims to fill significant gaps in women's health innovation by creating technologies that enhance diagnosis and treatment options. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation, further leveraging resources to advance its mission in the healthcare sector.

Biocius Life Sciences, Inc. is a company specializing in drug discovery research, established in 2009 and located in Woburn, Massachusetts. As a subsidiary of BioTrove, Inc., Biocius develops advanced technologies, including high-throughput mass spectrometry systems, to facilitate the drug discovery process. The company's innovative approach aims to enhance efficiency and accuracy in identifying potential therapeutic compounds, contributing to advancements in pharmaceutical research and development.

nVision Medical Corporation is a medical device company focused on addressing female health issues, specifically infertility caused by fallopian tube dysfunction and ovarian cancer detection. Founded in 2009 and based in Saratoga, California, nVision Medical develops innovative devices that allow clinicians to assess the health of previously inaccessible areas of the female reproductive tract. The company aims to fill significant gaps in women's health innovation by creating technologies that enhance diagnosis and treatment options. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation, further leveraging resources to advance its mission in the healthcare sector.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The company specializes in the development and commercialization of genomic tests aimed at diagnosing, staging, and guiding the treatment of lung cancer and other lung diseases. Allegro's molecular testing platform employs a genomic biomarker to assess changes in gene expression in the airway's epithelial cells, allowing for the early detection of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare providers with essential diagnostic information, facilitating quicker diagnosis and treatment decisions for patients.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

Vortex Medical is a medical device company focused on the design, development and commercialization.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The company specializes in the development and commercialization of genomic tests aimed at diagnosing, staging, and guiding the treatment of lung cancer and other lung diseases. Allegro's molecular testing platform employs a genomic biomarker to assess changes in gene expression in the airway's epithelial cells, allowing for the early detection of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare providers with essential diagnostic information, facilitating quicker diagnosis and treatment decisions for patients.

Vortex Medical is a medical device company focused on the design, development and commercialization.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

Hansen Medical, Inc. specializes in the development, manufacture, and sale of medical robotics aimed at enhancing the positioning, manipulation, and control of catheters and catheter-based technologies. The company offers the Sensei systems and Artisan Control Catheters, which are used in electrophysiology procedures to improve catheter navigation and control. Additionally, Hansen Medical provides the CoHesion 3D Visualization Module, a software tool that enhances physicians' ability to visualize catheter placement in three dimensions. Another key product is the Magellan Robotic System, which facilitates remote navigation and vessel cannulation using a telescoping, robotically steerable catheter. The company markets and supports its products through a combination of direct sales, distributors, and sales representatives. Founded in 2002 and headquartered in Mountain View, California, Hansen Medical operates as a subsidiary of Auris Surgical Robotics, Inc. since July 2016.

GI Dynamics, Inc. is a medical device company that focuses on developing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company's flagship product, EndoBarrier, is designed to help patients manage these conditions effectively. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts, and markets its products primarily in Europe, the Middle East, the Asia Pacific, and South America. The company serves healthcare providers and third-party distributors, aiming to provide innovative solutions for metabolic diseases.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

Novazyme Pharmaceuticals is a biotech startup that conducts research on a new experimental treatment for Pompe disease.

Novazyme Pharmaceuticals is a biotech startup that conducts research on a new experimental treatment for Pompe disease.

EndoVia Medical is a developer of physician-guided robotic systems for minimally invasive surgery. It develops the Laprotek system, a robotic instrument system for minimally invasive surgeries including general surgery, urology, gynecology, and bariatric surgery, and the ViaCath system, a user interface, and instrument control platform, that allows the surgeon to manipulate catheter instruments deep inside the patient.